演題詳細

ポスター / Poster

ポスター 20 (Poster 20) :Mantle Cell Lymphoma

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
三浦 勝浩 (Katsuhiro Miura):1
1:日本大学 血液膠原病内科
 
前へ戻る

Management of elderly patients with mantle cell lymphoma

演題番号 : PS-1-145

牧田 雅典 (Masanori Makita):1、清家 圭介 (Keisuke Seike):1、逸見 麻衣 (Mai Henmi):1、三道 康永 (Yasuhisa Sando):1、石川 立則 (Tatsunori Ishikawa):1、原 嘉孝 (Yoshitaka Hara):1、山本 和彦 (Kazuhiko Yamamoto):1、今城 健二 (Kenji Imajo):1

1:Department of Hematology and Oncology, Okayama City Hospital, Japan

 

BACKGROUND: The median age at mantle cell lymphoma (MCL) diagnosis is over 65 years, the majority of patients cannot receive dose-intensified regimens including stem cell transplantation. The ideal treatment of MCL in the elderly patient is uncertain. We herein evaluated the treatment of patients 70 years of age or older with MCL. RESULTS: In our institution, we investigated 10 patients (median age 66 years, range 50-85) with newly diagnosed MCL between January 2006 and December 2011. Of the 10 patients, 5 were 70 years of age or older. All patients were male and in Ann Arbor stage IV. According to the MCL International Prognostic Index, 3 patients were classified as intermediate risk, 2 patients as high risk. 3 patients received R-hyper-CVAD/MA with a dose reduction, and 2 R-CHOP as an induction therapy. Four of the 5 patients developed grade 3-4 febrile neutropenia, but there was no death due to toxicity. All patients achieved complete response. However, four of the 5 patients relapsed within 18 months and died of disease progression within 37 months (median 36 months, range 14-37). Only a 74-year-old male, who received R-CHOP followed by maintenance therapy with rituximab, remained in remission for 20 months. CONCLUSIONS: The R-hyper-CVAD/MA regimen is more aggressive as induction therapy than R-CHOP, however it is unclear that R-hyper-CVAD/MA improves overall survival compared with R-CHOP for elderly patients with MCL. R-CHOP followed by maintenance therapy with rituximab may be effective for elderly patients.

前へ戻る